ArticleClinical cancer research : an official journal of the American Association for Cancer Research2021
Neoadjuvant Pembrolizumab and High-Dose IFNα-2b in Resectable Regionally Advanced Melanoma.
Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 25 citations in OpenAlex.
- Long-term outcomes to neoadjuvant pembrolizumab based on pathological response for patients with resectable stage III/IV cutaneous melanoma.Annals of oncology : official journal of the European Society for Medical Oncology · 2023Trial
- A Systematic Review and Meta-Analysis of Surgical Feasibility and Outcomes Following Neoadjuvant Immune Checkpoint Inhibition in Resectable Stage III and IV Melanoma.Annals of surgical oncology · 2026Article
- Effect of neoadjuvant therapy on survival outcomes in patients with melanoma: a systematic review and meta-analysis.EClinicalMedicine · 2025Article
- Role of T cell exhaustion and tissue-resident memory T cells in the expression and prognosis of colorectal cancer.Scientific reports · 2025Article
- Improvement of the Anticancer Efficacy of PD-1/PD-L1 Blockade: Advances in Molecular Mechanisms and Therapeutic Strategies.MedComm · 2025Review
- The rapidly evolving paradigm of neoadjuvant immunotherapy across cancer types.Nature cancer · 2025Review
- A Review of Neoadjuvant PD-1 Inhibitors in the Setting of Cutaneous Malignancies.The Journal of clinical and aesthetic dermatology · 2025Review
- Stem Cell Origin of Cancer: Clinical Implications beyond Immunotherapy for Drug versus Therapy Development in Cancer Care.Cancers · 2024Article
- Educational Review: Clinical Application of Immune Checkpoint Blockade for the Treatment of Melanoma.Annals of surgical oncology · 2024Review
- Neoadjuvant Therapy in Melanoma: Where Are We Now?Current oncology reports · 2023Review
- PD‑1/PD‑L1 immune checkpoint inhibitors in neoadjuvant therapy for solid tumors (Review).International journal of oncology · 2023Review
- Combining PD-1/PD-L1 blockade with type I interferon in cancer therapy.Frontiers in immunology · 2023Review
- HLA-DR expression in melanoma: from misleading therapeutic target to potential immunotherapy biomarker.Frontiers in immunology · 2023Review
- Educational Review: Neoadjuvant Approaches to Melanoma.Annals of surgical oncology · 2022Review
- Molecular imaging to support cancer immunotherapy.Journal for immunotherapy of cancer · 2022Review
- Neoadjuvant immunotherapy of locoregionally advanced solid tumors.Journal for immunotherapy of cancer · 2022Article
- Systemic adjuvant therapy for high-risk cutaneous melanoma.Therapeutic advances in medical oncology · 2022Review
Corrections and comments
- Commented on by
Authors and funding
30 authors at 7 institutions in 1 country.
Funding
Abstract
purposeNeoadjuvant immunotherapy may improve the clinical outcome of regionally advanced operable melanoma and allows for rapid clinical and pathologic assessment of response. We examined neoadjuvant pembrolizumab and high-dose IFNα-2b (HDI) therapy in patients with resectable advanced melanoma. PATIENTS AND
methodsPatients with resectable stage III/IV melanoma were treated with concurrent pembrolizumab 200 mg i.v. every 3 weeks and HDI 20 MU/m
resultsA total of 31 patients were enrolled, and 30 were evaluable. At data cutoff (October 2, 2019), median follow-up for OS was 37.87 months (range, 33.2-43.47). Median OS and RFS were not reached. Radiographic ORR was 73.3% [95% confidence interval (CI): 55.5-85.8], with a 43% (95% CI: 27.3-60.1) pCR rate. None of the patients with a pCR have had a recurrence. HDI and pembrolizumab were discontinued in 73% and 43% of patients, respectively. Correlative analyses suggested that intratumoral PD-1/PD-L1 interaction and HLA-DR expression are associated with pCR (
conclusionsNeoadjuvant concurrent HDI and pembrolizumab demonstrated promising clinical activity despite high rates of treatment discontinuation. pCR is a prognostic indicator.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.